A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) (Vibrance-1)

June 8, 2026 updated by: Alkermes, Inc.

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
92

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Australia
    • New South Wales
      • Macquarie Park, New South Wales, Australia, 2113
        • Alkermes Investigator Site
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Alkermes Investigator Site
  • Belgium
      • Alken, Belgium, 3570
        • Alkermes Investigational Site
      • Bruges, Belgium, 8000
        • Alkermes Investigational Site
      • Namur, Belgium, 5101
        • Alkermes Investigational Site
  • Czechia
      • Prague, Czechia, 128 21
        • Alkermes Investigational Site
  • France
      • Bordeaux, France, 33000
        • Alkermes Investigational Site
      • Montpellier, France, 34295
        • Alkermes Investigational Site
  • Italy
      • Bologna, Italy, 40139
        • Alkermes Investigational Site
      • Milan, Italy, 20127
        • Alkermes Investigational Site
      • Verona, Italy, 37134
        • Alkermes Investigational Site
  • Netherlands
      • Heemstede, Netherlands, 2103 SW
        • Alkermes Investigational Site
      • Zwolle, Netherlands, 8025 BV
        • Alkermes Investigational Site
  • Spain
      • Barcelona, Spain, 08036
        • Alkermes Investigational Site
      • Madrid, Spain, 28036
        • Alkermes Investigational Site
      • Madrid, Spain, 28043
        • Alkermes Investigational Site
  • United States
    • California
      • Los Angeles, California, United States, 90025
        • Alkermes Investigational Site
      • Redwood City, California, United States, 94063
        • Alkermes Investigational Site
      • San Francisco, California, United States, 94107
        • Alkermes Investigator Site
      • Santa Ana, California, United States, 92705
        • Alkermes Investigational Site
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Alkermes Investigational Site
      • Colorado Springs, Colorado, United States, 80918
        • Alkermes Investigational Site
    • Florida
      • Brandon, Florida, United States, 33511
        • Alkermes Investigational Site
      • Brandon, Florida, United States, 33511
        • Alkermes Investigator Site
      • Miami, Florida, United States, 33176
        • Alkermes Investigational Site
      • Winter Park, Florida, United States, 32789
        • Alkermes Investigator Site
    • Georgia
      • Atlanta, Georgia, United States, 30328
        • Alkermes Investigational Site
      • Macon, Georgia, United States, 31210
        • Alkermes Investigational Site
      • Stockbridge, Georgia, United States, 30281
        • Alkermes Investigational Site
    • Illinois
      • Peoria, Illinois, United States, 61637
        • Alkermes Investigator Site
    • Michigan
      • Lansing, Michigan, United States, 48911
        • Alkermes Investigator Site
      • Sterling Heights, Michigan, United States, 48314
        • Alkermes Investigator Site
    • Nebraska
      • Lincoln, Nebraska, United States, 68506
        • Alkermes Investigator Site
    • New Jersey
      • Middletown, New Jersey, United States, 07748
        • Alkermes Investigational Site
    • North Carolina
      • Denver, North Carolina, United States, 28037
        • Alkermes Investigational Site
      • Huntersville, North Carolina, United States, 28708
        • Alkermes Investigational Site
    • Ohio
      • Canton, Ohio, United States, 44718
        • Alkermes Investigator Site
      • Cincinnati, Ohio, United States, 45227
        • Alkermes Investigational Site
      • Cincinnati, Ohio, United States, 45245
        • Alkermes Investigational Site
      • Dublin, Ohio, United States, 43017
        • Alkermes Investigational Site
    • Pennsylvania
      • Wyomissing, Pennsylvania, United States, 19610
        • Alkermes Investigational Site
    • South Carolina
      • Columbia, South Carolina, United States, 29201
        • Alkermes Investigational Site
    • Texas
      • Austin, Texas, United States, 78731
        • Alkermes Investigational Site
      • San Antonio, Texas, United States, 78229
        • Alkermes Investigational Site
      • The Woodlands, Texas, United States, 77380
        • Alkermes Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18-70 years of age
  • Has a BMI ≥18 and ≤40 kg/m2

  • Meets the diagnostic criteria of Narcolepsy type 1 according to ICSD-3-TR guidelines. Additionally, meets the following criteria:

    • Is HLA-DQB1*06:02-positive
    • Has residual excessive daytime sleepiness and cataplexy
  • Is willing and able to discontinue any medications prescribed for the management of narcolepsy symptoms for at least 14 days and for the duration of study
  • Is willing to adhere to additional protocol requirements

Exclusion Criteria:

  • Significant comorbid medical conditions, including other sleep, cardiovascular, psychiatric, hepatic or other disorders may be exclusionary; eligibility will be determined on an individual basis by the study investigator
  • Is currently pregnant, breastfeeding, or planning to become pregnant during the study
  • Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Drug: Placebo
Oral tablet containing matching placebo for once daily administration
Experimental: 4 mg ALKS 2680
Drug: ALKS 2680
Oral tablet of ALKS 2680 for once daily administration
Experimental: 6 mg ALKS 2680
Drug: ALKS 2680
Oral tablet of ALKS 2680 for once daily administration
Experimental: 8 mg ALKS 2680
Drug: ALKS 2680
Oral tablet of ALKS 2680 for once daily administration

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6
Time Frame: Baseline to Week 6
Baseline to Week 6

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Epworth Sleepiness Scale (ESS) from baseline to Week 6
Time Frame: Baseline to Week 6
Epsworth Sleepiness Scale is a 4-point scale used to measure excessive sleepiness from 0 (would never doze) to 3 (high chance of "dozing)
Baseline to Week 6
Incidence of adverse events
Time Frame: Up to 15 Weeks
Up to 15 Weeks
Mean weekly cataplexy rate (WCR) as derived by subject cataplexy diary
Time Frame: Measured at Week 5 and 6
Measured at Week 5 and 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Alkermes, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Study Medical Director, MD, Alkermes, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 24, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 19, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 2, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 5, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 11, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ALKS 2860-201

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Narcolepsy Type 1

Clinical Trials on ALKS 2680

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings